'On standalone basis
Quarter ended March 2025 compared with Quarter ended March 2024.
Net sales (including other operating income) of Pfizer has increased 8.28% to Rs 591.91 crore. Operating profit margin has jumped from 34.65% to 38.43%, leading to 20.10% rise in operating profit to Rs 227.50 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 16.42% to 11.78%. Purchase of finished goods cost rose from 17.40% to 23.27%. Employee cost decreased from 13.91% to 13.83%. Other expenses fell from 17.18% to 13.18%.
Other income fell 40.66% to Rs 44.58 crore. PBIDT rose 2.84% to Rs 272.08 crore. Provision for interest fell 61.29% to Rs 2.69 crore. Loan funds rose to Rs 40.78 crore as of 31 March 2025 from Rs 40.19 crore as of 31 March 2024. Inventories rose to Rs 475.92 crore as of 31 March 2025 from Rs 433.69...
Pleaselogin & subscribe to view the full report.
More Reports
|
|